Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging

NCT02650817 is registered in ClinicalTrials.gov with Stemline Therapeutics, Inc. as lead sponsor.

NCT NCT02650817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02650817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging
Lead sponsor
Stemline Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 1, 2016
Completion date
October 18, 2019
Enrollment
16 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer